Network meta-analysis of triple immunosuppressive therapies and standard of care for induction of remission of active lupus nephritis. (PubMed, Lupus) - Aug 6, 2026 - "In indirect pairwise comparisons, patients who received SOC+Tacrolimus compared to SOC+Rituximab (2.30 [1.27 to 4.20]), SOC+Anifrolumab (1.98 [1.07 to 3.52]), SOC+Ocrelizumab (1.81 [1.12 to 2.82]), and SOC+Abatacept (1.78 [1.07 to 2.91]) had significantly higher PRR...SOC+Belimumab, SOC+Obinutuzumab, SOC+Voclosporin and SOC+Tacrolimus ranked as effective therapies inducing PRR with SUCRA probability scores between 61.14% and 95.12%. Risk ratios of SAE and SIE were not significantly different among the immunosuppressive therapies.ConclusionIn patients with LN, induction therapies of SOC with calcineurin inhibitors had the highest relative benefit achieving remission of LN."
Clinical • Journal • Retrospective data • Glomerulonephritis • Immunology • Inflammatory Arthritis • Lupus • Lupus Nephritis • Nephrology
|
|
Adriana Dejman; Daniel Del Castillo Rix; Gabriel Contreras; Jair Munoz Mendoza; Juan Camilo Duque; Miguel Bandes; Sanjana Kota; Vinodh Mechery; Yiqin Zuo
|